New Drug Application on Track for LCFAOD A Rare Autosomal Recessive Disease

A recent article in the publication CheckOrphan announced encouraging results of a long term extension study sponsored by Ultragenyx involving UX007 (triheptanoin) in patients with long-chain fatty acid oxidation disorders…

Continue Reading New Drug Application on Track for LCFAOD A Rare Autosomal Recessive Disease

New Medicines Discovery Institute in Wales to Accelerate Fragile X Syndrome Research

Cardiff University in Wales has just announced the launch of their new Medicines Discovery Institute. It’s goal? To help accelerate the development of novel therapies for those living with conditions…

Continue Reading New Medicines Discovery Institute in Wales to Accelerate Fragile X Syndrome Research
Glioblastoma “Vaccine” Yields Hopeful Results at End of Phase 1b Trial
source: pixabay.com

Glioblastoma “Vaccine” Yields Hopeful Results at End of Phase 1b Trial

According to a publication from EurekAlert, results from a phase 1b clinical study of experimental glioblastoma “vaccine“ IGV-001 suggest that the treatment is well tolerated in humans. Additional data collected…

Continue Reading Glioblastoma “Vaccine” Yields Hopeful Results at End of Phase 1b Trial
Close Menu